Engineering RNA for Targeted siRNA Delivery and Medical Application

被引:220
作者
Guo, Peixuan [1 ]
Coban, Oana [1 ]
Snead, Nicholas M. [2 ]
Trebley, Joe
Hoeprich, Steve [2 ]
Guo, Songchuan
Shu, Yi [1 ]
机构
[1] Univ Cincinnati, Coll Med, Coll Engn, Dept Biomed Engn, Cincinnati, OH 45221 USA
[2] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA
关键词
Viral DNA packaging motor; RNA dimer; Trimer; Hexameric ring; DNA translocation; Bacteriophage phi29; pRNA; Procapsid; Viral assembly; siRNA; Targeted delivery; Gene therapy; RNA nanotechnology; Nanobiotechnology; Nanomedicine; SMALL INTERFERING RNA; RECEPTOR-MEDIATED ENDOCYTOSIS; DNA-PACKAGING MOTOR; IN-VITRO SELECTION; CHEMICAL-MODIFICATION; CANCER-CELLS; GENE-EXPRESSION; DOWN-REGULATION; INTERVENING SEQUENCE; THERAPEUTIC AGENTS;
D O I
10.1016/j.addr.2010.03.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA engineering for nanotechnology and medical applications is an exciting emerging research field. RNA has intrinsically defined features on the nanometre scale and is a particularly interesting candidate for such applications due to its amazing diversity, flexibility and versatility in structure and function. Specifically, the current use of siRNA to silence target genes involved in disease has generated much excitement in the scientific community. The intrinsic ability to sequence-specifically downregulate gene expression in a temporally- and spatially controlled fashion has led to heightened interest and rapid development of siRNA-based therapeutics. Although methods for gene silencing have been achieved with high efficacy and specificity in vitro, the effective delivery of nucleic acids to specific cells in vivo has been a hurdle for RNA therapeutics. This article covers different RNA-based approaches for diagnosis, prevention and treatment of human disease, with a focus on the latest developments of non-viral carriers of siRNA for delivery in vivo. The applications and challenges of siRNA therapy, as well as potential solutions to these problems, the approaches for using phi29 pRNA-based vectors as polyvalent vehicles for specific delivery of siRNA, ribozymes, drugs or other therapeutic agents to specific cells for therapy will also be addressed. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:650 / 666
页数:17
相关论文
共 196 条
[1]   Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer [J].
Ai, Zhihong ;
Yin, Lianhua ;
Zhou, Xianrong ;
Zhu, Ying ;
Zhu, Dongmei ;
Yu, Yinhua ;
Feng, Youji .
CANCER, 2006, 107 (04) :746-756
[2]   Opinion - Survivin, cancer networks and pathway-directed drug discovery [J].
Altieri, Dario C. .
NATURE REVIEWS CANCER, 2008, 8 (01) :61-70
[3]   Validating survivin as a cancer therapeutic target [J].
Altieri, DC .
NATURE REVIEWS CANCER, 2003, 3 (01) :46-54
[4]   HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector [J].
Anderson J. ;
Akkina R. .
AIDS Research and Therapy, 2 (1)
[5]   Synthesis and Characterization of a Carbon Nanotube-Dendron Series for Efficient siRNA Delivery [J].
Antonia Herrero, M. ;
Toma, Francesca M. ;
Al-Jamal, Khuloud T. ;
Kostarelos, Kostas ;
Bianco, Alberto ;
Da Ros, Tatiana ;
Bano, Fouzia ;
Casalis, Loredana ;
Scoles, Giacinto ;
Prato, Maurizio .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (28) :9843-9848
[6]   Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension [J].
Baneyx, G ;
Baugh, L ;
Vogel, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (08) :5139-5143
[7]   Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery [J].
Bellocq, NC ;
Pun, SH ;
Jensen, GS ;
Davis, ME .
BIOCONJUGATE CHEMISTRY, 2003, 14 (06) :1122-1132
[8]  
Bouvet P, 2000, METH MOL B, V148, P603
[9]   THE HAMMERHEAD RNA DOMAIN, A MODEL RIBOZYME [J].
BRATTY, J ;
CHARTRAND, P ;
FERBEYRE, G ;
CEDERGREN, R .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1216 (03) :345-359
[10]   RNAi therapeutics: a potential new class of pharmaceutical drugs [J].
Bumcrot, David ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Sah, Dinah W. Y. .
NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :711-719